| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
20-Deoxyingenol (2.5-10 mM; 24 hours) protects chondrocytes from cell death induced by tert-butyl hydroperoxide solution (TBHP; 100 μM) [2]. 20-Deoxyingenol (5-10 mM) can reduce the TBHP-induced upregulation of the apoptotic protein cleaved-caspase3 and the senescence protein p16INK4a in chondrocytes [2]. At concentrations below 10 mM, 20-Deoxyingenol (2.5–40 mM; 24 h) has no cytotoxic effect on chondrocytes [2]. In chondrocytes treated with TBHP, 20-Deoxyingenol (10 mM) restores autophagic flux over a 24-hour period [2]. 20-Deoxyingenol (4-10 mM; 24 hours) promotes nuclear levels of TFEB in TBHP-treated chondrocytes [2].
|
|---|---|
| ln Vivo |
In a mouse DMM model, 20-Deoxyingenol (20 mg/kg/d; intraperitoneal injection for 8 weeks) can slow the advancement of OA [2].
|
| Animal Protocol |
Animal/Disease Models: 10weeks old C57BL/6 male wild-type (WT) mice with unstable medial meniscus (DMM) [2]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection, one time/day, results for eight consecutive weeks Experimental Results: Compared with the DMM group, the joint space was slightly wider and bone density and calcification were diminished. Inhibits the reduction of hyaline cartilage (HC) thickness and reduces the disorder and hypertrophy of chondrocytes in mouse joint tissue after DMM surgery. The surface of articular cartilage is less eroded and contains more proteoglycans. There are more positive staining spots for LAMP1 and LC3 II, and fewer positive staining spots for cleaved-caspase3 and P16INK4a. Increased nuclear levels of TFEB. |
| References | |
| Additional Infomation |
20-Deoxyingenol has been reported in Euphorbia peplus and Euphorbia segetalis with data available.
|
| Molecular Formula |
C20H28O4
|
|---|---|
| Molecular Weight |
332.4
|
| Exact Mass |
332.198
|
| CAS # |
54706-99-9
|
| PubChem CID |
11290503
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
470.5±45.0 °C at 760 mmHg
|
| Flash Point |
252.4±25.2 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
3.51
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
24
|
| Complexity |
690
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4O)C)O)O)C
|
| InChi Key |
FOSYZKSOJUQLTD-NHPMXQBPSA-N
|
| InChi Code |
InChI=1S/C20H28O4/c1-9-6-12-14-13(18(14,4)5)7-11(3)19(17(12)23)8-10(2)16(22)20(19,24)15(9)21/h6,8,11-16,21-22,24H,7H2,1-5H3/t11-,12+,13-,14+,15-,16+,19+,20+/m1/s1
|
| Chemical Name |
(1S,4S,5S,6R,9S,10R,12R,14R)-4,5,6-trihydroxy-3,7,11,11,14-pentamethyltetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dien-15-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~150.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.52 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.52 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0084 mL | 15.0421 mL | 30.0842 mL | |
| 5 mM | 0.6017 mL | 3.0084 mL | 6.0168 mL | |
| 10 mM | 0.3008 mL | 1.5042 mL | 3.0084 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
